| pubmed-article:1512513 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C0023823 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C0969677 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C0311404 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C0242297 | lld:lifeskim |
| pubmed-article:1512513 | lifeskim:mentions | umls-concept:C1554963 | lld:lifeskim |
| pubmed-article:1512513 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1512513 | pubmed:dateCreated | 1992-9-28 | lld:pubmed |
| pubmed-article:1512513 | pubmed:abstractText | Much data has accumulated supporting a proatherogenic role for oxidized low density lipoprotein (Ox-LDL). Micronutrient antioxidants such as alpha-tocopherol, the principal lipid-soluble antioxidant, assume potential significance because levels can be manipulated by dietary measures without resulting in side effects. Co-incubation of LDL in vitro with alpha-tocopherol inhibits its oxidative modification. Hence the effect of dietary supplementation with alpha-tocopherol on the time course of copper-catalyzed oxidation of LDL was tested in a randomized placebo-controlled single-blind study. Two groups of 12 male subjects were given either placebo or alpha-tocopherol (800 IU/day) for a period of 12 weeks. Alpha-tocopherol therapy did not result in any side effects or exert an adverse effect on the plasma lipid and lipoprotein profile. While the lipid standardized alpha-tocopherol levels were similar at baseline, the supplemented group had 3.3-fold and 4.4-fold higher levels compared to placebo at 6 and 12 weeks, respectively. In the 15 subjects in whom both plasma and LDL alpha-tocopherol levels were quantitated, there was a significant correlation (r = 0.79, P less than 0.0001). At baseline there were no significant differences in the time course curves of thiobarbituric acid-reacting substances (TBARS) activity or conjugated diene formation between the alpha-tocopherol and placebo groups. However, at both 6 and 12 weeks the mean levels of TBARS activity and conjugated diene formation were lower in the alpha-tocopherol group; the most significant differences were manifest at the 3-h time point. Also at both 6 and 12 weeks the mean rate of oxidation was lower in the alpha-tocopherol group.2+_ | lld:pubmed |
| pubmed-article:1512513 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1512513 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1512513 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1512513 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1512513 | pubmed:issn | 0022-2275 | lld:pubmed |
| pubmed-article:1512513 | pubmed:author | pubmed-author:GrundyS MSM | lld:pubmed |
| pubmed-article:1512513 | pubmed:author | pubmed-author:JialalII | lld:pubmed |
| pubmed-article:1512513 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1512513 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:1512513 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1512513 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1512513 | pubmed:pagination | 899-906 | lld:pubmed |
| pubmed-article:1512513 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:meshHeading | pubmed-meshheading:1512513-... | lld:pubmed |
| pubmed-article:1512513 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1512513 | pubmed:articleTitle | Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. | lld:pubmed |
| pubmed-article:1512513 | pubmed:affiliation | Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas 75235-9052. | lld:pubmed |
| pubmed-article:1512513 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1512513 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1512513 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1512513 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1512513 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1512513 | lld:pubmed |
